Redefining treatment failure for pediatric acute leukemia in the era of minimal residual disease testing

Technologies for the detection of minimal residual disease (MRD) in leukemia and our understanding of the prognostic implications of MRD at different phases of treatment have significantly improved over the past decade. As a result, definitions of treatment failure based on bone marrow morphology by...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric hematology and oncology 2017-10, Vol.34 (6-7), p.395-408
Main Authors: Huynh, Van, Laetsch, Theodore W., Schore, Reuven J., Gaynon, Paul, O'Brien, Maureen M.
Format: Article
Language:English
Subjects:
Minimal residual disease
pediatric leukemia
treatment failure
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Technologies for the detection of minimal residual disease (MRD) in leukemia and our understanding of the prognostic implications of MRD at different phases of treatment have significantly improved over the past decade. As a result, definitions of treatment failure based on bone marrow morphology by light microscopy are becoming increasingly inadequate for clinical care and trial design. In addition, novel therapies that may have increased efficacy and decreased toxicity in the setting of MRD compared to overt disease are changing clinical practice and challenging investigators to redefine treatment failure, the role of disease surveillance in remission, and clinical trial eligibility in the era of MRD.
ISSN:0888-0018
1521-0669
DOI:10.1080/08880018.2017.1397073